Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
复制标题
DOI：
10.1182/blood.2019001694
复制
发表时间：
2019-09-12
期刊：
影响因子：
20.3
通讯作者：
Maus, Marcela V.
中科院分区：
文献类型：
--
作者：
Frigault, Matthew J.;Dietrich, Jorg;Maus, Marcela V.
靶向CD 19的嵌合抗原受体（CAR）T细胞已经成为用于复发性/难治性B细胞非霍奇金淋巴瘤的领先工程化T细胞疗法。由于严格的资格标准，导致美国食品和药物管理局批准的1/2期临床试验排除了中枢神经系统（CNS）受累的患者。在这里，我们报告了我们的机构经验，8继发性中枢神经系统淋巴瘤患者与商业tisagenlecleucel治疗。没有患者经历超过1级的神经毒性，也没有患者需要托珠单抗或类固醇来治疗CAR T细胞介导的毒性。生物标志物分析表明CAR T细胞扩增，尽管没有全身性疾病，并且早期反应评估证明了IV输注的CAR T细胞在CNS空间内的活性。
Chimeric antigen receptor (CAR) T cells targeting CD19 have emerged as a leading engineered T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The phase 1/2 clinical trials that led to US Food and Drug Administration approval excluded patients with central nervous system (CNS) involvement, due to strict eligibility criteria. Here, we report on our institutional experience with 8 secondary CNS lymphoma patients treated with commercial tisagenlecleucel. No patient experienced greater than grade 1 neurotoxicity, and no patient required tocilizumab or steroids for CAR T-cell-mediated toxicities. Biomarker analysis suggested CAR T-cell expansion, despite the absence of systemic disease, and early response assessments demonstrated activity of IV infused CAR T cells within the CNS space.